Vaccine immunotherapy in breast cancer treatment: promising, but still early.
about
Central role of liver in anticancer and radioprotective activities of Toll-like receptor 5 agonistFOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy.Aberrant PTPRO methylation in tumor tissues as a potential biomarker that predicts clinical outcomes in breast cancer patients.Preparation of triple-negative breast cancer vaccine through electrofusion with day-3 dendritic cellsTherapeutic antitumor efficacy of B cells loaded with tumor-derived autophagasomes vaccine (DRibbles)Alpha-Type 1 Polarized Dendritic Cells Loaded with Apoptotic Allogeneic Breast Cancer Cells Can Induce Potent Cytotoxic T Lymphocytes against Breast Cancer.Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice.CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome.Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy.The Toll-like receptor 5 agonist entolimod suppresses hepatic metastases in a murine model of ocular melanoma via an NK cell-dependent mechanism.HER2 as a target for breast cancer therapy.Therapeutic targeting of B7-H1 in breast cancer.Staphylococcal enterotoxin B/texosomes as a candidate for breast cancer immunotherapy.Generation of mature monocyte-derived dendritic cells in the presence of heparin and monocyte conditioned medium: phenotypic and functional comparison.Myeloid-derived suppressor cells are increased and correlated with type 2 immune responses, malnutrition, inflammation, and poor prognosis in patients with breast cancer.Linc-ROR induces epithelial-mesenchymal transition and contributes to drug resistance and invasion of breast cancer cells.Plasma phospholipase A2 activity may serve as a novel diagnostic biomarker for the diagnosis of breast cancer.In Vivo Applications of Single Chain Fv (Variable Domain) (scFv) Fragments
P2860
Q24623979-8A124E15-7637-4CBF-8B22-BFAC2C315AA8Q33320890-8D5C6943-9F92-43A6-ACED-064F9523B703Q33775528-0582E4EF-9565-410C-935B-B1A8BA9291D9Q33921487-6F783DB3-B68F-420F-A9DF-AFB49861F3B8Q34196895-CBBC650F-C919-4AC5-BC93-02A9512B53E8Q34771278-5D35A80B-10B7-4D66-9E5D-CDCCFEF04BBCQ35029583-AEB311EA-9E15-40D4-930C-84BE60210963Q36232078-AA8147D4-DD34-47FC-83B4-3E296D07D874Q36391595-EF1CAEA7-406F-40D5-90A9-247F3ABE40D3Q36771989-4B49E5DC-C247-4F20-BFC6-C840BBA7B768Q37705396-B319B371-29FB-4B73-9D83-6D68B5CD5AC2Q37922793-3D64F007-EDCC-476D-8EA1-6BF8B7A20BEEQ38846074-7ACCC842-6476-4D36-92C9-986AF47C465BQ40232811-393324F5-CA88-469B-B99A-824191038447Q41143084-AA118B21-92D2-408E-A763-1B38E1CEC08CQ47883740-E9817413-D9FB-4435-9AFD-D510F4ACE1CCQ52655121-C7F7ED87-6526-4585-8221-A75D6C481FCCQ56568322-506CA277-890C-42BB-A138-59D9CA2A3F0A
P2860
Vaccine immunotherapy in breast cancer treatment: promising, but still early.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Vaccine immunotherapy in breast cancer treatment: promising, but still early.
@en
type
label
Vaccine immunotherapy in breast cancer treatment: promising, but still early.
@en
prefLabel
Vaccine immunotherapy in breast cancer treatment: promising, but still early.
@en
P2093
P2860
P1476
Vaccine immunotherapy in breast cancer treatment: promising, but still early
@en
P2093
Aron Goldhirsch
Eloise Scarano
Gianluca Spitaleri
Manuela Dettori
Marzia Locatelli
P2860
P304
P356
10.1586/14737140.7.9.1225
P577
2007-09-01T00:00:00Z